Journal of Thrombosis and Thrombolysis

, Volume 29, Issue 3, pp 265–270 | Cite as

Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach

  • Uwe Raaz
  • Michael Buerke
  • Marese Busshardt
  • Lars Maegdefessel
  • Alexander Plehn
  • Baerbel Hauroeder
  • Karl Werdan
  • Axel Schlitt


Owing to its beneficial pharmacological profile, the low-molecular-weight heparin (LMWH) enoxaparin is increasingly being taken as an alternative to UFH in the treatment of ACS with an early invasive strategy and in elective percutaneous coronary interventions (PCI). Insufficient anticoagulation increases the risk of catheter thrombus formation during PCI. The aim of the present study was to test in vitro the hypotheses that (i) inhibiting thrombin or thrombin generation by administering LMWH is a critical intervention in preventing catheter thrombus formation and (ii) other LMWH such as certoparin or dalteparin are as effective as enoxaparin. Blood pre-treated with the anticoagulants of interest was continuously circulated through a guiding catheter by using a roller pump for a maximum experimental period of 60 min or until the catheter became occluded. Overall thrombus weight, anti-Xa activity and electron microscopic features such as deposits of platelets, erythrocytes and fibrin on the catheter surface were quantified as endpoints. All LMWH tested significantly reduced catheter thrombus generation comparable to UFH treatment whereas there was no difference between the specific LMWH with respect to catheter thrombus formation or deposition of platelets, erythrocytes and fibrin. Thrombus generation was found to negatively correlate with anti-Xa activity. The additional use of eptifibatide did not affect thrombus formation. These data suggest that modulating plasmatic coagulation by employing LMWH is critical for preventing catheter thrombus formation and at the same time offer a potential for administering LMWH other than enoxaparin, such as certoparin or dalteparin, in the setting of PCI.


PCI Low-molecular-weight heparin 



Acute coronary syndromes


Low-molecular-weight heparin(s)


Percutaneous coronary interventions


Unfractionated heparin


  1. 1.
    Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337:688–698. doi:10.1056/NEJM199709043371007 CrossRefPubMedGoogle Scholar
  2. 2.
    Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598–1660. doi:10.1093/eurheartj/ehm132 CrossRefPubMedGoogle Scholar
  3. 3.
    Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116:e148–e304. doi:10.1161/CIRCULATIONAHA.107.737312 CrossRefPubMedGoogle Scholar
  4. 4.
    Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation 117:296–329. doi:10.1161/CIRCULATIONAHA.107.188209 CrossRefPubMedGoogle Scholar
  5. 5.
    Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE et al (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355:1006–1017. doi:10.1056/NEJMoa052711 CrossRefPubMedGoogle Scholar
  6. 6.
    Natarajan MK, Velianou JL, Turpie AG, Mehta SR, Raco D, Goodhart DM et al (2006) A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J 151:175. doi:10.1016/j.ahj.2005.06.020 CrossRefPubMedGoogle Scholar
  7. 7.
    Grayburn PA, Willard JE, Brickner ME, Eichhorn EJ (1991) In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: evidence for inadequate heparinization. Cathet Cardiovasc Diagn 23:141–143. doi:10.1002/ccd.1810230219 CrossRefPubMedGoogle Scholar
  8. 8.
    Schlitt A, Rupprecht HJ, Reindl I, Schubert S, Hauroeder B, Carter JM et al (2008) In vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. Coron Artery Dis 19:279–284. doi:10.1097/MCA.0b013e328300426b CrossRefPubMedGoogle Scholar
  9. 9.
    Fareed J, Hoppensteadt D, Schultz C, Ma Q, Kujawski MF, Neville B et al (2004) Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr Pharm Des 10:983–999. doi:10.2174/1381612043452811 CrossRefPubMedGoogle Scholar
  10. 10.
    Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26(Suppl 1):31–38. doi:10.1055/s-2000-9497 CrossRefPubMedGoogle Scholar
  11. 11.
    Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA et al (2003) Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 146:628–634. doi:10.1016/S0002-8703(03)00165-0 CrossRefPubMedGoogle Scholar
  12. 12.
    Gibson CM, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M et al (2007) Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49:2238–2246. doi:10.1016/j.jacc.2007.01.093 CrossRefPubMedGoogle Scholar
  13. 13.
    Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S et al (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:45–54. doi:10.1001/jama.292.1.45 CrossRefPubMedGoogle Scholar
  14. 14.
    Borentain M, Montalescot G, Bouzamondo A, Choussat R, Hulot JS, Lechat P (2005) Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis. Catheter Cardiovasc Interv 65:212–221. doi:10.1002/ccd.20352 CrossRefPubMedGoogle Scholar
  15. 15.
    Stabile E, Nammas W, Salemme L, Sorropago G, Cioppa A, Tesorio T et al (2008) The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol 52:1293–1298. doi:10.1016/j.jacc.2008.07.026 CrossRefPubMedGoogle Scholar
  16. 16.
    Dana A, Nguyen CM, Cloutier S, Barbeau GR (2007) Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin. Catheter Cardiovasc Interv 70:847–853. doi:10.1002/ccd.21253 CrossRefPubMedGoogle Scholar
  17. 17.
    Vroman L (1964) Effects of hydrophobic surfaces upon blood coagulation. Thromb Diath Haemorrh 10:455–493PubMedGoogle Scholar
  18. 18.
    Plow EF, McEver RP, Coller BS, Woods VL Jr, Marguerie GA, Ginsberg MH (1985) Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 66:724–727PubMedGoogle Scholar
  19. 19.
    Vroman L, Adams AL, Fischer GC, Munoz PC (1980) Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood 55:156–159PubMedGoogle Scholar
  20. 20.
    Keuren JF, Wielders SJ, Willems GM, Morra M, Lindhout T (2002) Fibrinogen adsorption, platelet adhesion and thrombin generation at heparinized surfaces exposed to flowing blood. Thromb Haemost 87:742–747PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Uwe Raaz
    • 1
  • Michael Buerke
    • 1
  • Marese Busshardt
    • 1
  • Lars Maegdefessel
    • 1
  • Alexander Plehn
    • 1
  • Baerbel Hauroeder
    • 2
  • Karl Werdan
    • 1
  • Axel Schlitt
    • 1
  1. 1.Department of Medicine IIIMartin-Luther-University Halle-WittenbergHalle (Saale)Germany
  2. 2.Central Institute of the Federal Armed ForcesKoblenzGermany

Personalised recommendations